May 3, 2022

The stock price of Silk Road Medical, Inc. (Nasdaq: SILK) increased by 14.07% today. This is why. The stock price of Silk Road Medical, Inc. (Nasdaq: SILK) – a company focused on reducing the risk of stroke and its devastating impact – increased by 14.07% today. Investors are responding positively to the company announcing that the U.S. Food and Drug Administration (FDA) approved expanded indications for the ENROUTE stent to include patients at standard risk for adverse events from carotid endarterectomy (CEA). Previously, the stent was approved for use only in patients with anatomic or physiological criteria that put them at high risk of complications from more invasive surgical procedures. Silk Road Medical had previously submitted a PMA supplement, which included data extracted from the Vascular Quality Initiative. And the surveillance data included in the submission represented real-world outcomes in 20,264 patients considered at standard surgical risk. Those data demonstrated that use of Silk Road Medical’s TCAR system is statistically non-inferior in stroke and death outcomes to CEA, while showing a ninefold reduction in cranial nerve injury (CNI) (2.7% vs 0.3%, p=<0.001). KEY QUOTES: “This is the first time in history that a stent-based approach has demonstrated non-inferiority in stroke and death rates relative to CEA, with our TCAR system offering the added benefit of significantly reduced cranial nerve injury risk. This label expansion levels a playing field once dominated by open surgical techniques, allowing an expanded number of patients and physicians access to the benefits of a less invasive treatment option.” – Erica Rogers, President and Chief Executive Officer of Silk Road Medical “Pairing the right patient with the right treatment results in significantly improved physician and patient experiences and outcomes. I speak for the vascular community in welcoming this label expansion for TCAR and recognizing this as a vital advancement in the treatment paradigm for patients at risk of stroke. The decision regarding which patients to treat with TCAR is no longer restricted to patients at high surgical risk, providing a greater opportunity for the care-team to pursue the less invasive approach for a broader set of their patients. At Beth Israel Deaconess, going forward, we expect that the right treatment for the majority of our atherosclerotic carotid disease patients will be TCAR.” – Dr. Marc L. Schermerhorn, Chief, Division of Vascular and Endovascular Surgery at Beth Israel Deaconess Medical Center Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.